EMPERIAL-heart-failure-toplineresults EMPERIAL-heart-failure-toplineresults Update on the EMPERIAL-Reduced and EMPERIAL-Preserved studies, which assess exercise ability in adults with chronic heart failure with reduced and preserved ejection fraction
Bridging the gap in Generalized Pustular Psoriasis (GPP) Bridging the gap in Generalized Pustular Psoriasis (GPP) Emmanuelle Clerisme-Beaty, former Head of Clinical Development and Medical Affairs, Dermatology, discusses published insights from GPP patients.
Facing Pulmonary Fibrosis Facing Pulmonary Fibrosis Steve Jones talks about his experience facing his pulmonary fibrosis diagnosis.
Shared science for the best cat diabetes management Shared science for the best cat diabetes management Diabetes mellitus is a common endocrine disease with increasing prevalence in dogs and cats. Learn how science's made management easier.
CHMP_opinion_nintedanib_ILD_PF CHMP_opinion_nintedanib_ILD_PF Nintedanib received a CHMP positive opinion for the treatment of patients with other chronic fibrosing ILDs with a progressive phenotype beyond IPF
Boehringer Ingelheim strong growth pipeline acceleration 2023 Boehringer Ingelheim strong growth pipeline acceleration 2023 Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Spesolimab meets key endpoint for GPP flare prevention Spesolimab meets key endpoint for GPP flare prevention Spesolimab meets primary and key secondary endpoint for prevention of generalized pustular psoriasis flares
Advancing health: Our impactful R&D investments Advancing health: Our impactful R&D investments Discover how we’re investing in sustainable impact with an unwavering commitment to research and development
emperor-preserved-heart-failure-full-data emperor-preserved-heart-failure-full-data Full results from EMPEROR-Preserved trial demonstrate significant improvement in heart failure outcomes in adults with preserved ejection fraction
Technologies Technologies We are expanding our global network of technology partners Learn more about partnering with us.
Boehringer Ingelheim 2022 half year results Boehringer Ingelheim 2022 half year results First half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline
Pioneering for progress in generalized pustular psoriasis Pioneering for progress in generalized pustular psoriasis An event, bringing together 170 delegates from across the world to strive for excellence in care of GPP
The generalized pustular psoriasis (GPP) Forum 2023 The generalized pustular psoriasis (GPP) Forum 2023 An executive summary of the activities and key takeaways from the GPP Forum 2023
vaxxitek® hvt + ibd + nd vaxxitek® hvt + ibd + nd Bursal Disease-Marek's disease-Newcastle disease vaccine, serotype 3, live Marek's disease vector; the vaccine includes a diluent
FDA-CRL-T1D FDA-CRL-T1D US FDA issues complete response letter for treatment of adults with type 1 diabetes
The geography of pet parasites is changing The geography of pet parasites is changing Climate change facilitates new pet parasites way beyond ticks and flea bites in dogs and cats
Boehringer Ingelheim leader in hatchery vaccination Boehringer Ingelheim leader in hatchery vaccination Boehringer Ingelheim is a leader in hatchery vaccination with vector vaccines.
Patient Organizations Patient Organizations Boehringer Ingelheim’s core principles and vision guide our work with patient organisations.
FDA Grants BI 1015550 Breakthrough Therapy Designation for IPF FDA Grants BI 1015550 Breakthrough Therapy Designation for IPF FDA Grants BI 1015550 Breakthrough Therapy Designation for Idiopathic Pulmonary Fibrosis
2020 European PRRS Research Award sponsorship 2020 European PRRS Research Award sponsorship 2020 European PRRS Research Award: Boehringer Ingelheim calls for submissions
10 things you should know about rabies 10 things you should know about rabies 10 things you should know about rabies
Partnership Boehringer Ingelheim Lifebit health data Partnership Boehringer Ingelheim Lifebit health data Boehringer Ingelheim and Lifebit announce partnership to capture transformational value of health data
Biopharmaceuticals: large molecules, enormous potential Biopharmaceuticals: large molecules, enormous potential Researching, developing and manufacturing biopharmaceuticals is a highly complex and lengthy process, but it has enormous potential.